|
1
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pignata S, Cannella L, Leopardo D, Pisano
C, Bruni GS and Facchini G: Chemotherapy in epithelial ovarian
cancer. Cancer Lett. 303:73–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tothill RW, Tinker AV, George J, Brown R,
Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro
B, et al: Novel molecular subtypes of serous and endometrioid
ovarian cancer linked to clinical outcome. Clin Cancer Res.
14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takano M, Kikuchi Y, Yaegashi N, Kuzuya K,
Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, et al:
Clear cell carcinoma of the ovary: A retrospective multicentre
experience of 254 patients with complete surgical staging. Br J
Cancer. 94:1369–1374. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takano M, Sugiyama T, Yaegashi N, Suzuki
M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, et
al: The impact of complete surgical staging upon survival in
early-stage ovarian clear cell carcinoma: A multi-institutional
retrospective study. Int J Gynecol Cancer. 19:1353–1357. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takano M, Tsuda H and Sugiyama T: Clear
cell carcinoma of the ovary: Is there a role of histology-specific
treatment? J Exp Clin Cancer Res. 31:532012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu H and Jove R: The STATs of cancer-new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kong H, Zhang Q, Zeng Y, Wang H, Wu M,
Zheng T, Zeng Y and Shi H: Prognostic significance of
STAT3/phosphorylated-STAT3 in tumor: A meta-analysis of
literatures. Int J Clin Exp Med. 8:8525–8539. 2015.PubMed/NCBI
|
|
10
|
Rosen DG, Mercado-Uribe I, Yang G, Bast RC
Jr, Amin HM, Lai R and Liu J: The role of constitutively active
signal transducer and activator of transcription 3 in ovarian
tumorigenesis and prognosis. Cancer. 107:2730–2740. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Min H and Wei-hong Z: Constitutive
activation of signal transducer and activator of transcription 3 in
epithelial ovarian carcinoma. J Obstet Gynaecol Res. 35:918–925.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Permuth-Wey J, Fulp WJ, Reid BM, Chen Z,
Georgeades C, Cheng JQ, Magliocco A, Chen DT and Lancaster JM:
STAT3 polymorphisms may predict an unfavorable response to
first-line platinum-based therapy for women with advanced serous
epithelial ovarian cancer. Int J Cancer. 138:612–619. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yanaihara N, Hirata Y, Yamaguchi N,
Noguchi Y, Saito M, Nagata C, Takakura S, Yamada K and Okamoto A:
Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor
(IL-6R) signaling pathway inhibition in clear cell carcinoma of the
ovary. Mol Carcinog. 55:832–841. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
You S, Li R, Park D, Xie M, Sica GL, Cao
Y, Xiao ZQ and Deng X: Disruption of STAT3 by niclosamide reverses
radioresistance of human lung cancer. Mol Cancer Ther. 13:606–616.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lateef M, Zargar SA, Khan AR, Nazir M and
Shoukat A: Successful treatment of niclosamide- and
praziquantel-resistant beef tapeworm infection with nitazoxanide.
Int J Infect Dis. 12:80–82. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ren X, Duan L, He Q, Zhang Z, Zhou Y, Wu
D, Pan J, Pei D and Ding K: Identification of niclosamide as a new
small-molecule inhibitor of the STAT3 signaling pathway. ACS Med
Chem Lett. 1:454–459. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiang D, Yuan Y, Chen L, Liu X, Belani C
and Cheng H: Niclosamide, an anti-helminthic molecule,
downregulates the retroviral oncoprotein Tax and pro-survival Bcl-2
proteins in HTLV-1-transformed T lymphocytes. Biochem Biophys Res
Commun. 464:221–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sasa H, Ishii K, Hirata J, Kikuchi Y,
Nagata I, Kawai T, Senoo A, Sugita M, Sugishita T and Tenjin Y:
Establishment and characterization of a CA-125-producing human
ovarian clear cell carcinoma cell line. Hum Cell. 6:279–286.
1993.(In Japanese). PubMed/NCBI
|
|
19
|
Anglesio MS, George J, Kulbe H,
Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA,
House CM, et al: IL6-STAT3-HIF signaling and therapeutic response
to the angiogenesis inhibitor sunitinib in ovarian clear cell
cancer. Clin Cancer Res. 17:2538–2548. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arend RC, Londoño-Joshi AI, Samant RS, Li
Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM and
Buchsbaum DJ: Inhibition of Wnt/β-catenin pathway by niclosamide: A
therapeutic target for ovarian cancer. Gynecol Oncol. 134:112–120.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
King ML, Lindberg ME, Stodden GR, Okuda H,
Ebers SD, Johnson A, Montag A, Lengyel E, MacLean Ii JA and Hayashi
K: WNT7A/β-catenin signaling induces FGF1 and influences
sensitivity to niclosamide in ovarian cancer. Oncogene.
34:3452–3462. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jin Y, Lu Z, Ding K, Li J, Du X, Chen C,
Sun X, Wu Y, Zhou J and Pan J: Antineoplastic mechanisms of
niclosamide in acute myelogenous leukemia stem cells: Inactivation
of the NF-kappaB pathway and generation of reactive oxygen species.
Cancer Res. 70:2516–2527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen M, Wang J, Lu J, Bond MC, Ren XR,
Lyerly HK, Barak LS and Chen W: The anti-helminthic niclosamide
inhibits Wnt/Frizzled1 signaling. Biochemistry. 48:10267–10274.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sack U, Walther W, Scudiero D, Selby M,
Kobelt D, Lemm M, Fichtner I, Schlag PM, Shoemaker RH and Stein U:
Novel effect of antihelminthic Niclosamide on S100A4-mediated
metastatic progression in colon cancer. J Natl Cancer Inst.
103:1018–1036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pan JX, Ding K and Wang CY: Niclosamide,
an old antihelminthic agent, demonstrates antitumor activity by
blocking multiple signaling pathways of cancer stem cells. Chin J
Cancer. 31:178–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fujiwara Y, Takaishi K, Nakao J, Ikeda T,
Katabuchi H, Takeya M and Komohara Y: Corosolic acid enhances the
antitumor effects of chemotherapy on epithelial ovarian cancer by
inhibiting signal transducer and activator of transcription 3
signaling. Oncol Lett. 6:1619–1623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abubaker K, Luwor RB, Escalona R, McNally
O, Quinn MA, Thompson EW, Findlay JK and Ahmed N: Targeted
disruption of the JAK2/STAT3 pathway in combination with systemic
administration of paclitaxel inhibits the priming of ovarian cancer
stem cells leading to a reduced tumor burden. Front Oncol.
4:752014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Abubaker K, Luwor RB, Zhu H, McNally O,
Quinn MA, Burns CJ, Thompson EW, Findlay JK and Ahmed N: Inhibition
of the JAK2/STAT3 pathway in ovarian cancer results in the loss of
cancer stem cell-like characteristics and a reduced tumor burden.
BMC Cancer. 14:3172014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gritsina G, Xiao F, O'Brien SW, Gabbasov
R, Maglaty MA, Xu RH, Thapa RJ, Zhou Y, Nicolas E, Litwin S, et al:
Targeted blockade of JAK/STAT3 signaling inhibits ovarian carcinoma
growth. Mol Cancer Ther. 14:1035–1047. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhong LX, Li H, Wu ML, Liu XY, Zhong MJ,
Chen XY, Liu J and Zhang Y: Inhibition of STAT3 signaling as
critical molecular event in resveratrol-suppressed ovarian cancer
cells. J Ovarian Res. 8:252015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Colomiere M, Ward AC, Riley C, Trenerry
MK, Cameron-Smith D, Findlay J, Ackland L and Ahmed N: Cross talk
of signals between EGFR and IL-6R through JAK2/STAT3 mediate
epithelial-mesenchymal transition in ovarian carcinomas. Br J
Cancer. 100:134–144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
U.S. National Library of Medicine,
National Cancer Institute (NCI), . Ruxolitinib phosphate,
paclitaxel, and carboplatin in treating patients with stage III–IV
epithelial ovarian, fallopian tube, or primary peritoneal cancer.
https://clinicaltrials.gov/ct2/show/NCT02713386March
18–2016
|
